HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 06-05-2009, 07:16 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
research into how to prevent lymphedema with sentinel lymph node dissection-Progress!

Axillary Reverse Mapping Technique Useful in Protecting Lymphatic Drainage: Presented at ASBS [Doctor's Guide]
SAN DIEGO — April 27, 2009 — Surgeons utilising the axillary reverse mapping (ARM) technique find that a significant number of patients are vulnerable to arm lymphatics disruption during axillary lymphadenectomy, which may explain the lymphoedema seen after axillary lymph node dissection (ALND) and/or sentinel lymph node biopsy (SLNB), researchers noted here at the American Society of Breast Surgeons (ASBS) 10th Annual Meeting.
This follow-up study involved patients undergoing SLNB (n = 220), as well as some patients undergoing SLNB +- ALND (n = 37). The study was conducted between May 2006 and September 2008; median patient age was 60.3 +- 11.3 years.
"Since surgeons all do SNLB differently — which is why we see differences in outcome — the clinical significance of the lymphatics identified by ARM may help prevent lymphoedema," stated lead author Cristiano Boneti, MD, University of Arkansas for Medical Sciences and Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, speaking here at an oral presentation on April 26.
Dr. Boneti's group injected technetium sulphur colloid into the subareolar plexus for SLNB procedures. After SLN localisation was assured, 2 to 5 mL of dermal blue dye was injected in the upper inner arm for localisation of lymphatics draining the arm.
SLNB +- ALND was performed through an incision in the axilla.
Data were collected on hot versus blue nodes; variations in ARM lymphatic drainage that may have had an impact on SLNB; any crossover between the hot and the blue lymphatics; incidence of metastases compared to arm lymphatics when crossover was present, and final pathological nodal diagnosis.
Lymphatics draining the arm were near or in the sentinel lymph gland field in 40.6% of the cases, which placed the patient at risk for disruption if not identified and preserved during an SLNB and/or ALND procedure. Crossover of the blue ARM lymphatics with the hot SLN was seen in only 6 patients (2.8%).
Final analysis of ARM results showed that 37.8% of patients were vulnerable to arm lymphatic disruption during axillary lymphadenectomy. The ARM node was rarely the sentinel node; in cases of crossover, none of the lymph nodes contained metastases.
Disruption of the blue ARM node due to proximity with the hot SLN, the study said, explained the high rate of lymphoedema seen after SLNB — a rate that Dr. Boneti termed "phenomenal."
^^^^^^^
ASBS 2009: ABSTRACT: Axillary Reverse Mapping to Identify and Protect Lymphatics Draining the Arm During Axillary Lymphadenectomy (PDF) [American Society of Breast Surgeons]
Objectives: Our initial results utilizing the axillary reverse mapping (ARM) procedure to identify lymphatics draining the arm during sentinel lymph node biopsy (SLNB) with or without axillary lymph node dissection (ALND) may explain why lymphedema still occurs during SLNB and, to a greater extent, during ALND. The objective of this study is to provide an update on our initial results with this new technique.
Method: This institutional review board-approved study from May 2006 to September 2008 involved patients undergoing SLNB ± ALND. Technetium sulfur colloid was injected in the subareolar plexus for SLNB. After SLN localization was assured, 2-5 ml of dermal blue dye were injected in the upper inner arm for localization of lymphatics draining the arm (ARM). The SLNB ± ALND was then performed through an incision in the axilla. Data was collected on identification rates of hot versus blue nodes; variations in ARM lymphatic drainage that may impact SLNB; crossover between the hot and the blue lymphatics and, when crossover was present, the incidence of metastases to arm lymphatics; and final pathological nodal diagnosis.
Results: Median age was 60.3 ± 11.3 years. Results: are shown in the table below.... Lymphatics draining the arm were near or in the SLN field 40.6% of the cases, placing the patient at risk for disruption if not identified and preserved during an SLNB and/or ALND. Crossover of the blue ARM lymphatics with the hot SLN was seen in only 6 (2.8%) of the patients. In this initial series, another 12 (5.6%) of blue ARM lymphatics were juxtaposed to the hot SLNB but able to be preserved. Fifteen blue lymph nodes draining the arm were excised and were negative even in positive axillae.
Conclusions: Analysis of ARM results show that a significant number of patients are vulnerable to arm lymphatic disruption (37.8%) during axillary lymphadenectomy. It may explain the cause lymphedema seen after ALND and even SLNB. ARM demonstrated that arm lymphatics cross over with the SLN drainage of the breast only in a minority of cases (2.8%), that is the ARM node is rarely the sentinel node. When crossover was identified, none of these lymph nodes contained metastases. Maturation of ongoing studies will elucidate whether identifying and preserving the ARM blue nodes may translate into a lower incidence of postoperative lymphedema.
Lani is offline   Reply With Quote
Old 06-05-2009, 08:22 AM   #2
michka
Senior Member
 
michka's Avatar
 
Join Date: Feb 2007
Location: Paris, France
Posts: 858
Thank you Lani for this interesting article. I often thought that if more surgeons were women they would have more concerns about potential complications after ALND or mastectomies. So many women suffer from lymphoedema and PMPS. I was disapointed that our surgeons did not try to improve the surgical techniques of breast operations when they are now starting to graft faces. They must consider that the most important part is getting rid of the tumors and preventing recurrence. They are right but they could also work on improving their techniques. It is good news that they are trying to progress. Michka
__________________
08.2006 3 cm IDC Stage 2-3, HER2 3+ ER+90% PR 20%
FEC, Taxol+ Herceptin, Mastectomy, Radiation, Herceptin 1 year followed by Tykerb 1 year,Aromasin /Faslodex

12.2010 Mets to liver,Herceptin+Tykerb
03.2011 Liver resection ER+70% PR-
04.2011 Herceptin+Navelbine+750mg Tykerb
06.2011 Liver ned, Met to sternum. Added Zometa 09.2011 Cyberknife for sternum
11.2011 Pet clear. Stop Navelbine, continuing on Hercpetin+Tykerb+Aromasin
02.2012 Mets to lungs, nodes, liver
04.2012 TDM1, Ned in 07.2012
04.2015 Stop TDM1/Kadcyla, still Ned, liver problems
04.2016 Liver mets. Back on Kadcyla
08.2016 Kadcyla stopped working. mets to liver lungs bones
09.2016 Biopsy to liver. no more HER2, still ER+
09.2016 CMF Afinitor/Aromasin/ Xgeva.Met to eye muscle Cyberknife
01.2017 Gemzar/Carboplatin/ Ibrance/Faslodex then Taxotere
02.2017 30 micro mets to brain breathing getting worse and worse
04.2017 Liquid biopsy/CTC indicates HER2 again. Start Herceptin with Halaven
06.2017 all tumors shrunk 60% . more micro mets to brain (1mm mets) no symptoms
michka is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:59 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter